Professor and Eveleigh Fenton Chair of Applied Microbiology, Rutgers University, USA
25th Oct 2021
09:00 to 16:00 (GMT +8)
The meeting is full. Please email [email protected] to be added to the waiting list.
Date: 25th October 2021 (Monday)
Time: 09:00 to 16:00 (GMT +8)
Event structure: Presentations and Panel Discussion
Registration fee: Complimentary access
Recent microbiome research demonstrates the crucial role of microbial communities in human health. The microbiome, now associated with immunity, disease, and behaviour, is paramount in maintaining our health and keeping us away from disease. With numerous pre-clinical and clinical studies actively being conducted, the microbiome is transitioning from a descriptive to a mechanistic science.
It is inevitable that leveraging the microbiome is a promising prospect to improve human health, as it enables us to step forward and manipulate microbiota in a variety of ways. Given the growing interest, research and industry experts are working together towards bringing microbiome discoveries to the market, making it an unprecedented investment opportunity alongside large-scale collaborations underway and sequencing data in the public domain. In the time of COVID-19, microbiome is set to make waves in the scientific and medical worlds as an essential prerequisite for future rational interventions.
This meeting will discuss the current state of knowledge in this fast-moving research area, ranging from development of new methods of studying the microbial communities to how the microbiome affects health, disease, and the therapeutics industry for the benefit of humankind and the environment.
Associate Professor, College of Computer Science and Technology, Qingdao University, China
Associate Professor, Department of Molecular Biology & Biochemistry and Co-Director, UCI Microbiome Center, University of California, Irvine, USA
Associate Professor and Deputy Director – Research, Australian Centre for Water and Environmental Biotechnology (formerly AWMC), The University of Queensland, Australia
MGI Tech Co., Ltd. (referred to as MGI) is committed to building core tools and technology to lead life science through intelligent innovation. MGI focuses on R&D, production and sales of DNA sequencing instruments, reagents, and related products to support life science research, agriculture, precision medicine and healthcare. MGI is a leading producer of clinical high-throughput gene sequencers, and its multi-omics platforms include genetic sequencing, medical imaging, and laboratory automation.
ChunLab/EzBiome is a microbiome company transforming healthcare through data-driven microbiome therapeutics and diagnostics. We provide world-class genomics, metagenomics, and microbiome sequencing services & bioinformatics platforms. Pioneered in precision taxonomy, and the world’s largest curated reference database, we offer the most accurate microbial identification and microbiome profiling solutions to revolutionize microbiology. Our most extensively cited (11,000+) and widely used (50,000+ users) EzBioCloud platform, together with our industry-leading sequencing solutions, delivers quality, rigor, and reliability in genomics and microbiome studies, and significantly expedite microbiome biomarker discovery for diagnostics and therapeutics applications.
The meeting is full please email [email protected] with your full contact details to be added to the waiting list.
With over a decade of experience in hosting life science events, Global Engage is your ideal partner to either devise an agenda for you or work with you and your speakers to promote the online event to our extensive databases.
For further details please contact
Telephone +44 (0) 7538 368 764 or
email [email protected]
Telephone: +603 2117 5193 or
email [email protected]